You are here

Article Text

Article menu

Download PDFPDF

Poster Presentations
P84 Regular monitoring of anti-C1q antibodies can be of help to predict lupus nephritis (LN) exacerbations
  1. Marta Calatroni1,2,
  2. Emanuele Conte2,3,
  3. Federica Bello4,5,
  4. Matteo Stella1,2,
  5. Francesco Reggiani1,2 and
  6. Gabriella Moroni1,2
  1. 1Dept. of Biomedical Sciences, Humanitas University, Pieve Emanuele Milan, Italy
  2. 2Nephrology and Dialysis Division, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
  3. 3Dept. of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
  4. 4Dept. of Experimental and Clinical Medicine, University of Firenze, Florence, Italy
  5. 5Internal Interdisciplinary Medicine Unit, Careggi University Hospital, Florence, Italy

Abstract

Objective This study explores the role of monitoring anti-C1q antibodies to predict lupus nephritis (LN) flares.

Methods In a cohort of LN patients, their clinical/histological/immunological/therapeutic features, at start of study, at 6 and 12 months after beginning therapy (reported in table 1) were tested at univariable and multivariable analysis with Cox proportional hazard models to identify predictors of renal flares occurring after 12-months follow-up. Anti-C1q antibodies were measured by ELISA-test (normal value were <20UA, high value >80UA).

Results Fifty-three LN patients (84.9% were females, with a median age of 39 (29–47) years old, 10 patients with class III, 39 class IV and 4 class V at kidney biopsy categorized by ISN/RPS classification), 36 enrolled at LN diagnosis and 17 at a LN flare, entered this study. At baseline, 17 patients had acute kidney dysfunction (32%), and 17 had nephrotic syndrome (32%). Forty patients received methylprednisolone pulses as induction therapy, the others oral prednisone (0.5–1mg/kg/day) associated with an immunosuppressive agent. During a median follow-up of 62.5 (45.63–78.62) months, renal flares occurred in 10 patients (18.86%). All flares occurred after 12-months observation, in median 28.19 (24.84–39.38) months (2 nephritic and 8 proteinuric flares). Among clinical/histological and therapeutic features at start of the study and at 6 months, only anti-C1q antibodies (OR:1.0098; CI:1.0004–1.0193; p=0.04; OR:1.0268; CI:1.0126–1.1041; p=0.001 respectively) predicted renal flares. At 12 months, anti-C1q antibodies (OR:1.0180; CI:1.0064–1.10297; p=0.0020), antiC1q >40 UA (OR:4.4345; CI:1.1536–17.0462; p=0.0310), proteinuria (OR:1.8537; CI:1.1237–3.0578; p=0.0160), and no use of hydroxychloroquine (OR:0.2561; CI:0.1009–1.2778; p=0.0370) predicted renal flares at univariable analysis. At multivariable analysis, antiC1q >40 UA (OR:5.2421; CI:1.3338–20.6019; p=0.0183) and no use of Hydroxychloroquine (OR: 0.2080; CI:0.0538–0.7573; p=0.0183) were the independent predictors of renal flares (figure 1).

Conclusion With the limitations of a small study, our results suggest that a high titer of anti-C1q at baseline and failure to normalize (or reducing <40 UA) during the follow-up are helpful in identifying patients who will develop renal flares. Hydroxychloroquine use reduces the risk of lupus flares.

View this table:
Abstract P84 Table 1

Clinical and histological characteristics at Lupus Nephritis diagnosis. Legend: SLE: systemic lupus erythematosus, n.: number

Abstract P84 Figure 1
Abstract P84 Figure 1

Survival free of flares. The difference between curves was evaluated by the log-rank test. 1a Survival free of flares in patients who had at 12 months antiC1q > 40 (1) vs those who had antiC1q <40 (0) p=0.031 0. 1b Survival free of flares in patients who were at 12 months in treatment (1) or not (0) with Hydroxychloroquine p=0.0370

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ .

https://doi.org/10.1136/lupus-2024-el.138

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.